Navigation Links
ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
Date:1/31/2008

TORONTO, Jan. 31 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that it has entered into a cGMP contract manufacturing agreement for its Trop-2 Signal Transduction Antibody Program with Laureate Pharma, a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. ARIUS' Trop-2 antibody program targets a novel marker that has been linked in the scientific literature to aggressive cancers including pancreatic, colon, breast and prostate cancer.

"The initiation of manufacturing for our second drug candidate demonstrates our ability to execute on our milestones and move multiple candidates from the ARIUS pipeline of drug candidates forward," said Dr. David S. Young, President and Chief Executive Officer of ARIUS. "Laureate Pharma has a track record of expertise in biopharmaceutical manufacturing, including capabilities in both clinical and commercial-grade materials and will provide us with a supply of our Trop-2 targeting drug necessary to begin our preclinical studies in the first quarter of 2008 in preparation for human clinical trials."

"Our specialized experience in the manufacture of monoclonal antibodies makes us an ideal partner to support ARIUS and the manufacturing of their Trop-2 Signal Transduction Antibody," said Robert J. Broeze, Ph.D., President & CEO of Laureate. "As with all of our Life Science client companies, we will work closely with the ARIUS team to help them achieve their manufacturing objectives."

ARIUS' Trop-2 Signal Transduction Antibody Program has produced the only unconjugated antibody currently in development targeting this novel marker. Trop-2 is a protein expressed on the cell-surface and found in many cancer indications including pancreatic, colon, breast and prostate cancer. The target is thought to be a key part of the expansive MAPK pathway.
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
2. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
3. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
4. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
5. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
6. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
7. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
8. ARIUS to present at Chinese Global Financial Forum
9. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
10. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
11. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Earlier this year in a June 24 ... the Adult Stem Cell Technology Center, LLC ( ASCTC ... appreciated unique property of adult tissue stem cells. ... in the Past, Important for the Future,” embodied the ... gave the address at the 4th World Congress on ...
(Date:12/24/2014)... Texas (PRWEB) December 23, 2014 ... methyl mercaptan such as its definition, classification, ... presents product specification, manufacturing process, and product ... technology and applications. The analysis also covers ... marketing channels, industry development trend and proposals. ...
(Date:12/24/2014)... China Biologic Products, Inc. (NASDAQ: CBPO, ... integrated plasma-based biopharmaceutical company in China ... Shandong Taibang Biological Products Co. Ltd., has received ... Food and Drug Administration (the "CFDA") for its ... in the Company,s public filings, the CFDA inspected ...
(Date:12/24/2014)... Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... filed a Clinical Trial Application (CTA) with the ... Agency (MHRA) seeking regulatory approval to initiate clinical trials ... Citrate. Contingent on the Company receiving CTA ... I trial to assess the safety, tolerability and dose ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... Friday announced the availability of RFID 360, a ... major retailer and Department of Defense compliance. RFID 360 ... RFID implementation environment and schedule. , ,The first software ... others, is RFID Data Manager. Data Manager is designed ...
... engine company, set the business world abuzz with the ... so it released data about its financial performance that ... analysts however, criticized the company and its founders for ... proposed for its stock offering. While some trepidation is ...
... Note: The Wisconsin Technology Network is committed to ... and deployment of technology. We salute the administration and ... help spread the adoption health technology. If you ... should attend the following event. , ,The ...
Cached Biology Technology:RedPrairie announces RFID 360 compliance software 2Why Google Matters 2Why Google Matters 3The doctor is in: Thompson prescribes better health information technology 2The doctor is in: Thompson prescribes better health information technology 3The doctor is in: Thompson prescribes better health information technology 4
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
(Date:12/10/2014)... Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ... the ultimate driver in long-term mass consumer adoption of ...
(Date:12/10/2014)... DUBLIN , Dec. 08, 2014 Research ... announced the addition of the "Biometrics Market ... http://photos.prnewswire.com/prnh/20130307/600769 ... for projects such as rural banking and upgradation ... major trends witnessed in the market. Besides the ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... of chromosomes, and even a small change in this structure ... can lead to severe physical impairment. So it,s no ... frequently a contributing factor, says Prof. Ron Shamir of the ... Now Prof. Shamir and his former doctoral students Michal Ozery-Flato ...
... release is available in Spanish . ... because of their characteristics, produce a certain amount of social ... fact that they are subjected to moral conflicts and ethical ... very necessary from a social perspective, as in the case ...
... Institute scientist Matthias von Herrath, M.D., a world leader in ... seeing his discoveries translated into new therapies to better treat ... may soon get his chance as head of a new ... in 2012 by Novo Nordisk, a global healthcare company specializing ...
Cached Biology News:Patterns of chromosome abnormality: The key to cancer? 2Moral imagination as a key to overcoming work-related stigmas 2La Jolla Institute scientist takes quest to conquer Type 1 diabetes to the next level 2
Rabbit polyclonal to Dishevelled 2 ( Abpromise for all tested applications). entrezGeneID: 1856 SwissProtID: O14641...
... Rabbit polyclonal to ErbB 2 - ... for all tested applications). ... AENPEYLGLDVPV conjugated to KLH, corresponding to ... Human c-ErbB2 Entrez ...
Anti human PPAR gamma2 mouse monoclonal antibody...
Anti-Potassium Channel Kv2.2 Immunogen: Synthetic peptide from rat Kv2.2. Available Date: 38376...
Biology Products: